Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ174MR)

This product GTTS-WQ174MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ174MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7523MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ9912MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ8685MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ1787MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ13655MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ5617MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ5217MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ10489MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW